Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.

AbstractRationale:Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disord